USANA Health Sciences, Inc. - 10-Q Summary
Business Context and Reporting Period
Company: USANA Health Sciences, Inc. (USNA)
Reporting Period: Quarter ended September 28, 2024 (Q3 2024)
Business Model: Global direct-selling of nutritional and personal care products.
Key Metric: Approximately 452,000 active Customers worldwide as of September 28, 2024.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Net Sales | $200,221 | $213,365 | $640,890 | $699,927 |
| Gross Profit | $160,964 | $170,836 | $518,231 | $565,553 |
| Gross Margin | 80.4% | 80.1% | 80.9% | 80.8% |
| Net Earnings | $10,607 | $11,347 | $37,576 | $47,022 |
| Diluted EPS | $0.56 | $0.59 | $1.96 | $2.43 |
| Operating Cash Flow (9M) | $55,207 | $44,618 | ||
| Cash & Equivalents (End of Period) | ||||
| Debt (Line of Credit) | $0 | $0 | $0 | $0 |
Note: All financial figures are in thousands except per share data and percentages.
Material Changes vs. Prior Period
- Revenue Decline: Q3 Net Sales decreased 6.2% ($13.1M) year-over-year. The decline was driven by a reduction in active Customers and lower average spend per customer due to challenging economic conditions in key markets.
- Profitability: Net Earnings decreased 6.5% in Q3. Gross margin improved slightly to 80.4% due to lower material costs in China and favorable product mix, offset by currency headwinds.
- Customer Base: Total active Customers decreased by 2.6% (12,000) year-over-year to 452,000. Declines were noted in North Asia (-16.3%) and Americas/Europe (-9.8%), partially offset by growth in Greater China (+5.7%).
- Geographic Performance: Asia Pacific sales declined 5.8% (constant currency), while Americas and Europe declined 7.4% (constant currency). China remains the largest market, contributing 51.1% of Q3 sales.
Guidance, Outlook, and Risks
- Outlook: Management cites a challenging economic environment affecting customer acquisition and spending. No specific forward-looking financial guidance was provided in this text.
- Capital Allocation: The company repurchased $9.5M of common stock in the first nine months of 2024. $61.7M remains authorized for future repurchases.
- Liquidity: Cash and cash equivalents increased to $364.9M. The company has a $75M revolving credit facility with no outstanding balance.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 28, 2024, due to material weaknesses in Information Technology General Controls (ITGCs). Remediation is ongoing and expected to be completed by the end of fiscal 2024.
- Risks: Key risks include dependence on the direct-selling model, regulatory uncertainties in China (BabyCare subsidiary), geopolitical tensions, and foreign currency volatility.
Investor Verification Checklist
- ITGC Remediation: Verify the progress of remediation efforts regarding the material weaknesses in internal controls over financial reporting.
- China Exposure: Monitor regulatory changes in China and the ability to remit profits from the BabyCare subsidiary to the U.S.
- Customer Trends: Track the recovery of active Customer counts and average spend per customer in North Asia and the Americas.
- Currency Impact: Assess the sensitivity of future earnings to fluctuations in foreign exchange rates, particularly the U.S. dollar.
- Debt Covenants: Confirm continued compliance with the Credit Facility covenants (EBITDA and leverage ratios), though currently no debt is outstanding.